Home Transmembrane Transporters Proton Pump

Proton Pump

Proton Pump Products

  • All (22)
  • Proton Pump Inhibitors (22)
  • New Proton Pump Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.
Nature, 2024, 626(8000):874-880
Nature, 2024, 626(8000):874-880
Cell, 2024, 187(21):6055-6070.e22
S1389 Omeprazole Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
J Extracell Vesicles, 2024, 13(4):e12426
J Extracell Vesicles, 2024, 13(4):e12426
J Transl Med, 2024, 22(1):676
S4845 Rabeprazole Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
J Extracell Vesicles, 2024, 13(4):e12426
Med Oncol, 2024, 41(8):188
PLoS Genet, 2022, 18(3):e1010128
S5658 Omeprazole Sodium Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.
Theranostics, 2021, 11(5):2364-2380
Theranostics, 2021, 11(5):2364-2380
J Virol, 2021, JVI.00190-21
S2105 Pantoprazole Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Med Oncol, 2024, 41(8):188
Int J Mol Sci, 2022, 23-158572
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
S1354 Lansoprazole Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.
Front Cell Dev Biol, 2021, 9:655559
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S4075 Zinc Pyrithione Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Biol Reprod, 2019, 100(2):468-478
Cell Syst, 2017, 4(6-:600-610
S4099 Dexlansoprazole Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S5608 Pantoprazole sodium hydrate Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
J Virol, 2021, JVI.00190-21
S4538 Pantoprazole sodium Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
J Virol, 2021, JVI.00190-21
S5885 Rabeprazole Related Compound E Rabeprazole Related Compound E (Rabeprazole thioether) is an active metabolite of rabeprazole, which is a proton pump inhibitor.
Stem Cells Int, 2022, 2022:1396735
S5502 Ilaprazole sodium Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.
J Virol, 2021, JVI.00190-21
S3666 Ilaprazole Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
Med Oncol, 2024, 41(8):188
J Virol, 2021, JVI.00190-21
S4212 Tenatoprazole Tenatoprazole (TU-199,STU-Na) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.
J Virol, 2021, JVI.00190-21
S4665 Rabeprazole sodium Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.
J Virol, 2021, JVI.00190-21
S5058 Revaprazan Hydrochloride Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S1743 Esomeprazole magnesium Esomeprazole Magnesium(NEXIUM) is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2222 PF-3716556 PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.
E4988New Vonoprazan Fumarate Vonoprazan Fumarate(TAK-438), is a potent, orally active inhibitor of proton pump, specifically a potassium-competitive acid blocker (P-CAB), inhibiting H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. It exhibits potent antisecretory activity and can be used in research of acid-related disease.
E4878New Lansoprazole sodium Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.
S5847 Ethacrynate Sodium Ethacrynate Sodium (ethacrynic acid sodium) is the sodium salt form of ethacrynic acid, which inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
S6438 Ufiprazole Ufiprazole (Omeprazole sulfide) is an intermediate used in the production of the gastric proton pump inhibitors omeprazole and esomeprazole.
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.
Nature, 2024, 626(8000):874-880
Nature, 2024, 626(8000):874-880
Cell, 2024, 187(21):6055-6070.e22
S1389 Omeprazole Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
J Extracell Vesicles, 2024, 13(4):e12426
J Extracell Vesicles, 2024, 13(4):e12426
J Transl Med, 2024, 22(1):676
S4845 Rabeprazole Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
J Extracell Vesicles, 2024, 13(4):e12426
Med Oncol, 2024, 41(8):188
PLoS Genet, 2022, 18(3):e1010128
S5658 Omeprazole Sodium Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.
Theranostics, 2021, 11(5):2364-2380
Theranostics, 2021, 11(5):2364-2380
J Virol, 2021, JVI.00190-21
S2105 Pantoprazole Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Med Oncol, 2024, 41(8):188
Int J Mol Sci, 2022, 23-158572
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
S1354 Lansoprazole Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.
Front Cell Dev Biol, 2021, 9:655559
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S4075 Zinc Pyrithione Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Biol Reprod, 2019, 100(2):468-478
Cell Syst, 2017, 4(6-:600-610
S4099 Dexlansoprazole Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S5608 Pantoprazole sodium hydrate Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
J Virol, 2021, JVI.00190-21
S4538 Pantoprazole sodium Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
J Virol, 2021, JVI.00190-21
S5885 Rabeprazole Related Compound E Rabeprazole Related Compound E (Rabeprazole thioether) is an active metabolite of rabeprazole, which is a proton pump inhibitor.
Stem Cells Int, 2022, 2022:1396735
S5502 Ilaprazole sodium Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.
J Virol, 2021, JVI.00190-21
S3666 Ilaprazole Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
Med Oncol, 2024, 41(8):188
J Virol, 2021, JVI.00190-21
S4212 Tenatoprazole Tenatoprazole (TU-199,STU-Na) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.
J Virol, 2021, JVI.00190-21
S4665 Rabeprazole sodium Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.
J Virol, 2021, JVI.00190-21
S5058 Revaprazan Hydrochloride Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S1743 Esomeprazole magnesium Esomeprazole Magnesium(NEXIUM) is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2222 PF-3716556 PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.
E4988New Vonoprazan Fumarate Vonoprazan Fumarate(TAK-438), is a potent, orally active inhibitor of proton pump, specifically a potassium-competitive acid blocker (P-CAB), inhibiting H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. It exhibits potent antisecretory activity and can be used in research of acid-related disease.
E4878New Lansoprazole sodium Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.
S5847 Ethacrynate Sodium Ethacrynate Sodium (ethacrynic acid sodium) is the sodium salt form of ethacrynic acid, which inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
S6438 Ufiprazole Ufiprazole (Omeprazole sulfide) is an intermediate used in the production of the gastric proton pump inhibitors omeprazole and esomeprazole.
E4988New Vonoprazan Fumarate Vonoprazan Fumarate(TAK-438), is a potent, orally active inhibitor of proton pump, specifically a potassium-competitive acid blocker (P-CAB), inhibiting H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. It exhibits potent antisecretory activity and can be used in research of acid-related disease.
E4878New Lansoprazole sodium Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.

Choose Selective Proton Pump Inhibitors

Proton PumpSignaling Pathway

Proton Pump信号通路图
Tags: proton pump inhibition | PPI therapy | PPI medication | PPIs drugs | proton pump inhibitors medications | proton pump inhibitor drugs | PPI treatment | proton pump inhibitors list | proton pump inhibitor therapy | proton pump inhibitor treatment | proton pump inhibitors cancer | PPI prescription | proton pump inhibitor guidelines | proton pump inhibitor function | proton pump inhibitors contraindications | PPI contraindications proton pump inhibitor review